The U.S. Supreme Court in Shute v. Carnival Cruise Lines, 499 U.S. 585 (1991) held the Shutes, who were injured on a Carnival Cruise ship in waters off Mexico, must file suit in Florida pursuant to the forum selection provision printed on the back of their ticket.   The Shutes filed suit in their home state of Washington.  The cruise ship departed from California.  Shute is still one of the most far reaching holdings enforcing adhesion-like forum selection provisions.  The Shutes also had a strong argument that they lacked notice of the forum selection/choice of law provisions.  

In the recent running aground of the Italian Costa Concordia operated by Costa Crocier, which is controlled by Carnival, the ship departed near Rome.  Approximately 120 United States citizens were on board and two may still be missing.  With respect to notice of the forum selection and choice of law provisions, information is much easier to obtain now than it was when Shute was decided.  For example, Carnival now posts its ticket contract online.  Carnival’s contract includes a mandatory arbitration provision as well as a forum selection clause, limits on liability, and restricted statute of limitations periods.   Costa Crocier also posts their ticket contract online.  The Costa contract includes forum selection, arbitration and choice of law provisions at Section 2.    

For claims involving personal injury or death, the Costa contract includes a forum selection clause for Broward County, Florida for cruises that depart from, visit or return to a U.S. port.  In contrast, U.S. port related economic loss claims are subject to an arbitration provision.  Under the Costa contract, any cruise that does not depart from, visit or return to a U.S. port, all claims must be filed in Genoa, Italy, and Italian law applies.  The Costa contract also includes a jury waiver provision.  

When a district court applies a forum selection provision, it usually does so via 28 U.S.C. § 1404, whereas a state court would dismiss the case.  Italy is not a district to which a federal case can be transferred, so dismissal is likely remedy if court enforces forum selection provisions for U.S. citizen cases filed in their home state, or even in Florida.  See e.g., Albemarle Corp. v. Astrazeneca U.K, Ltd., 628 F.3d 643, 651 (4th Cir. 2010) (applying English law / federal common law to enforce forum selection clause via dismissal).  Albemarle also suggests that Costa Concordia related claims filed in the U.S. would still be analyzed under the four factor “unreasonableness” test set forth in M/S Bremen v. Zapata Off–Shore Co., 407 U.S. 1 (1972) (holding forum selection clause may be found unreasonable if “(1) [its] formation was induced by fraud or over-reaching; (2) the complaining party ‘will for all practical purposes be deprived of his day in court’ because of the grave inconvenience or un-fairness of the selected forum; (3) the fundamental unfairness of the chosen law may deprive the plaintiff of a remedy; or (4) [its] enforcement would contravene a strong public policy of the forum state.”).     

Here, proponents of avoiding Costa Crocier’s forum selection clause and choice of Italian law may argue factors two, three and four.  An analysis of Italian law related to factor three is beyond the scope of this blog post!
Bookmark and Share

 

It is well known that manufacturers do not have to make the safest possible products.  Rather, manufacturers are prohibited from making unreasonably dangerous products.  And one of the biggest factors in determining whether or not a product is unreasonably dangerous is the existence of a feasible alternative design.  Concerning for manufacturers though, the First Circuit just upheld a verdict against a manufacturer even though the plaintiff failed to prove the existence of a feasible alternative design.    

In Osorio v. One World Tech., Inc., No. 10-1824 (1st Cir. Oct. 5, 2011), the plaintiff sued the maker of a table saw after he cut his arm while using the saw.  The plaintiff argued that the saw should have contained a mechanism that stops and retracts the blade when the blade comes into contact with flesh.  To bolster this argument, the plaintiff brought the inventor of the mechanism to testify on his behalf. 

The manufacturer argued that the mechanism is not a feasible alternative design.  The mechanism makes the saw larger and heavier, which would substantially change the use of the light, portable saw.  Also, the mechanism has a tendency to retract when the blade gets wet, meaning that it cannot be used outside.   Further, each time the blade retracts, the blade must be replaced.  Additionally, the mechanism makes the $179 saw almost twice as expensive, adding $150 to the retail price.  It is no surprise then that none of the major saw manufacturers use the mechanism. 

Even after hearing all of this information, the jury found that the saw was defective and awarded the plaintiff $1.5 million.  The manufacturer appealed, arguing that the plaintiff failed to prove the existence of a feasible alternative design.  On appeal, the First Circuit determined that a plaintiff does not have to prove the existence of a feasible alternative design to win a design defect claim.  Rather, the existence of a feasible alternative design is just one factor in the "unreasonably dangerous" determination.  As such, the court upheld the jury's verdict. 

If you're shaking your head, you're not alone.  While this case may not sit well with manufacturers, at least it provides a reminder that they should think twice before trying design defect cases in states where plaintiffs do not have to prove the existence of a feasible alternative design.   

 

William F. Auther is a partner with an active trial practice in product liability and business litigation and Kelly M. McInroy is an associate in the Phoenix office of Bowman and Brooke LLP.  

Bookmark and Share

 

An unnamed company has taken the first step in challenging the Consumer Product Safety Commission's (CPSC) online complaint database.  No information is currently listed in Pacer, the federal court filing system, but the Washington Post reported that a complaint was filed Monday in Maryland District Court.  The company that filed the suit is listed as "Company Doe" to protect its name – the exact reason that it filed the complaint in the first place. 

On August 14, 2008, the Consumer Product Safety Improvement Act became law and mandated that the CPSC create an online portal for customers to post complaints about products that can either injure children or pose fire, electrical, chemical, or mechanical hazards.  The Act sought to provide consumers with timely information about potentially unsafe products, so consumers would not have to wait for a recall to get the information.  However, the database has been criticized because of accuracy issues and the burden it places on manufacturers. 

Anyone can file a report in the database, found at www.SaferProducts.gov. , but a report is not eligible for publication unless it contains: (1) a description of the product; (2) the name of the manufacturer; (3) a description of the injury or risk of injury caused by the product; (4) the date that the incident occurred or risk of injury was discovered; (5) the type of reporter (consumer, agency, child service provider, etc.); (6) the reporter's name and address (this is not published); (7) the reporter's acknowledgement that the report is true and accurate; and (8) whether or not the reporter wants the information published. 

Once a report is filed online, the CPSC has five days to review it before sending it to the manufacturer.  However, the CPSC's "review" only entails ensuring that the minimum publication requirements have been met; the CPSC does not conduct any type of fact-finding investigation.  Instead, the burden is placed on the manufacturer to prove that the report is untrue, and it has just ten days to prove it.   If a report ends up being published, manufacturers can have their comments published with the report, but the CPSC does not always process comments in time to publish them the same day the report is published, and posting a comment is little consolation if a report is untrue. 

Since its inception, the database has been criticized for not requiring more information to reduce inaccuracies, such as a product serial number.  And the fact that manufacturers have to conduct all of the fact-finding and essentially prove themselves innocent seems a bit backwards considering anyone with access to a computer can file a report. 

Given these circumstances, it was only a matter of time before a company stepped up and challenged the system.  Consistent with argument that the database needlessly harms the reputation of manufacturers, the company has filed the lawsuit anonymously.  Whether or not the court will allow the company to remain "Company Doe" presents another question altogether.  But either way, this case could have major consequences for the CPSC database, and is definitely one to watch. 

William F. Auther is a partner with an active trial practice in product liability and business litigation and Kelly M. McInroy is a law clerk in the Phoenix office of Bowman and Brooke LLP.  

Bookmark and Share

 

(originally posted at Tortini <http://schachtmanlaw.com/reference-manual-on-scientific-evidence-v3-0-disregarding-study-validity-in-favor-of-the-whole-gamish/> on October 14, 2011.)

There is much to digest in the new Reference Manual on Scientific Evidence, third edition (RMSE 3d).  Much of what is covered is solid information on the individual scientific and technical disciplines covered.  Although the information is easily available from other sources, there is some value in collecting the material in a single volume for the convenience of judges.  Of course, given that this information is provided to judges from an ostensibly neutral, credible source, lawyers will naturally focus on what is doubtful or controversial in the RMSE.

I have already noted some preliminary concerns, however, with some of the comments in the Preface, by Judge Kessler and Dr. Kassirer.  See “New Reference Manual’s Uneven Treatment of Conflicts of Interest.”  In addition, there is a good deal of overlap among the chapters on statistics, epidemiology, and medical testimony.  This overlap is at first blush troubling because the RMSE has the potential to confuse and obscure issues by having multiple authors address them inconsistently.  This is an area where reviewers should pay close attention.

From first looks at the RMSE 3d, there is a good deal of equivocation between encouraging judges to look at scientific validity, and discouraging them any meaningful analysis by emphasizing inaccurate proxies for validity, such as conflicts of interest.  (As I have pointed out, the new RSME did not do quite so well in addressing its own conflicts of interest.  See “Toxicology for Judges – The New Reference Manual on Scientific Evidence (2011).”) The strengths of the chapter on statistical evidence, updated from the second edition, remain, as do some of the strengths and flaws of the chapter on epidemiology.  I hope to write more about each of these important chapters at a later date.

The late Professor Margaret Berger has an updated version of her chapter from the second edition, “The Admissibility of Expert Testimony,” RSME 3d 11 (2011).  Berger’s chapter has a section criticizing “atomization,” a process she describes pejoratively as a “slicing-and-dicing” approach.  Id. at 19.  Drawing on the publications of Daubert-critic Susan Haack, Berger rejects the notion that courts should examine the reliability of each study independently. Id. at 20 & n. 51 (citing Susan Haack, “An Epistemologist in the Bramble-Bush: At the Supreme Court with Mr. Joiner,” 26 J. Health Pol. Pol’y & L. 217–37 (1999).  Berger contends that the “proper” scientific method, as evidenced by works of the International Agency for Research on Cancer, the Institute of Medicine, the National Institute of Health, the National Research Council, and the National Institute for Environmental Health Sciences, “is to consider all the relevant available scientific evidence, taken as a whole, to determine which conclusion or hypothesis regarding a causal claim is best supported by the body of evidence.” Id. at 19-20 & n.52.  This contention, however, is profoundly misleading.  Of course, scientists undertaking a systematic review should identify all the relevant studies, but some of the “relevant” studies may well be insufficiently reliable (because of internal or external validity issues) to answer the research question at hand. All the cited agencies, and other research organizations and researchers, exclude studies that are fundamentally flawed, whether as a result of bias, confounding, erroneous data analyses, or related problems.  Berger cites no support for the remarkable suggestion that scientists do not make “reliability” judgments about available studies when assessing the “totality of the evidence.”

Professor Berger, who had a distinguished career as a law professor and evidence scholar, died in November 2010.  She was no friend of Daubert, but remarkably her antipathy has outlived her.  Her critical discussion of “atomization” cites the notorious decision in Milward v. Acuity Specialty Products Group, Inc., 639 F.3d 11, 26 (1st Cir. 2011), which was decided four months after her passing. Id. at 20 n.51. (The editors note that the published chapter was Berger’s last revision, with “a few edits to respond to suggestions by reviewers.”)

Professor Berger’s contention about the need to avoid assessments of individual studies in favor of the whole gamish must also be rejected because Federal Rule of Evidence 703 requires that each study considered by an expert witness “qualify” for reasonable reliance by virtue of the study’s containing facts or data that are “of a type reasonably relied upon by experts in the particular field forming opinions or inferences upon the subject.”  One of the deeply troubling aspects of the Milward decision is that it reversed the trial court’s sensible decision to exclude a toxicologist, Dr. Martyn Smith, who outran his headlights on issues having to do with a field in which he was clearly inexperienced – epidemiology.

Scientific studies, and especially epidemiologic studies, involve multiple levels of hearsay.  A typical epidemiologic study may contain hearsay leaps from patient to clinician, to laboratory technicians, to specialists interpreting test results, back to the clinician for a diagnosis, to a nosologist for disease coding, to a national or hospital database, to a researcher querying the database, to a statistician analyzing the data, to a manuscript that details data, analyses, and results, to editors and peer reviewers, back to study authors, and on to publication.  Those leaps do not mean that the final results are untrustworthy, only that the study itself is not likely admissible in evidence.

The inadmissibility of scientific studies is not problematic because Rule 703 permits testifying expert witnesses to formulate opinions based upon facts and data, which are not themselves admissible in evidence. The distinction between relied upon, and admissible, studies is codified in the Federal Rules of Evidence, and in virtually every state’s evidence law.

Referring to studies, without qualification, as admissible in themselves is wrong as a matter of evidence law.  The error has the potential to encourage carelessness in gatekeeping expert witnesses’ opinions for their reliance upon inadmissible studies.  The error is doubly wrong if this approach to expert witness gatekeeping is taken as license to permit expert witnesses to rely upon any marginally relevant study of their choosing.  It is therefore disconcerting that the new Reference Manual on Science Evidence (RMSE 3d) fails to make the appropriate distinction between admissibility of studies and admissibility of expert witness opinion that has reasonably relied upon appropriate studies.

Consider the following statement from the chapter on epidemiology:

“An epidemiologic study that is sufficiently rigorous to justify a conclusion that it is scientifically valid should be admissible,184 as it tends to make an issue in dispute more or less likely.185"

RMSE 3d at 610.  Curiously, the authors of this chapter have ignored Professor Berger’s caution against slicing and dicing, and speak to a single study’s ability to justify a conclusion. The authors of the epidemiology chapter seem to be stressing that scientifically valid studies should be admissible.  The footnote emphasizes the point:

See DeLuca v. Merrell Dow Pharms., Inc., 911 F.2d 941, 958 (3d Cir. 1990); cf. Kehm v. Procter & Gamble Co., 580 F. Supp. 890, 902 (N.D. Iowa 1982) (“These [epidemiologic] studies were highly probative on the issue of causation—they all concluded that an association between tampon use and menstrually related TSS [toxic shock syndrome] cases exists.”), aff’d, 724 F.2d 613 (8th Cir. 1984). Hearsay concerns may limit the independent admissibility of the study, but the study could be relied on by an expert in forming an opinion and may be admissible pursuant to Fed. R. Evid. 703 as part of the underlying facts or data relied on by the expert. In Ellis v. International Playtex, Inc., 745 F.2d 292, 303 (4th Cir. 1984), the court concluded that certain epidemiologic studies were admissible despite criticism of the methodology used in the studies. The court held that the claims of bias went to the studies’ weight rather than their admissibility. Cf. Christophersen v. Allied-Signal Corp., 939 F.2d 1106, 1109 (5th Cir. 1991) (“As a general rule, questions relating to the bases and sources of an expert’s opinion affect the weight to be assigned that opinion rather than its admissibility. . . .”).”

RMSE 3d at 610 n.184 (emphasis in bold, added).  This statement, that studies relied upon by an expert in forming an opinion may be admissible pursuant to Rule 703, is unsupported by Rule 703 and the overwhelming weight of case law interpreting and applying the rule.  (Interestingly, the authors of this chapter seem to abandon their suggestion that studies relied upon “might qualify for the learned treatise exception to the hearsay rule, Fed. R. Evid. 803(18), or possibly the catchall exceptions, Fed. R. Evid. 803(24) & 804(5),” which was part of their argument in the Second Edition of the RMSE.  RMSE 2d at 335 (2000).)  See also RMSE 3d at 214 (discussing statistical studies as generally “admissible,” but acknowledging that admissibility may be no more than permission to explain the basis for an expert’s opinion).

The cases cited by the epidemiology chapter, Kehm and Ellis, both involved “factual findings” in public investigative or evaluative reports, which were independently admissible under Federal Rule of Evidence 803(8)(C).  See Ellis, 745 F.2d at 299-303; Kehm, 724 F.2d at 617-18.  As such, the cases hardly support the chapter’s suggestion that Rule 703 is a rule of admissibility for epidemiologic studies.

Here the RMSE, in one sentence, confuses Rule 703 with an exception to the rule against hearsay, which would prevent the statistical studies from being received in evidence.  The point is reasonably clear, however, that the studies “may be offered” to explain an expert witness’s opinion.  Under Rule 705, that offer may also be refused. The offer, however, is to “explain,” not to have the studies admitted in evidence.

The RMSE is certainly not alone in advancing this notion that studies are themselves admissible.  Other well-respected evidence scholars lapse into this position:

“Well conducted studies are uniformly admitted.”

David L. Faigman, et al., Modern Scientific Evidence:  The Law and Science of Expert Testimony v.1, § 23:1,at 206 (2009)

Evidence scholars should not conflate admissibility of the epidemiologic (or other) studies with the ability of an expert witness to advert to a study to explain his or her opinion.  The testifying expert witness really has no need to become a conduit for off-hand comments and opinions in the introduction or discussion section of relied upon articles, and the wholesale admission of such hearsay opinions undermines the court’s control over opinion evidence.  Rule 703 authorizes reasonable reliance upon “facts and data,” not every opinion that creeps into the published literature.

Nathan Schachtman is in private practice in New York City, and is a lecturer-in-law at the Columbia University Law School.

Bookmark and Share

 

(originally posted on www.masstortsstateoftheart.com on October 4, 2011)

Well, the Reference Manual on Scientific Evidence: Third Edition is out. And the fix is in.
Think we exaggerate? How about this little gem from the Preface: "Judges and juries, however, must consider financial conflicts of interest when assessing scientific testimony. The threshold for pursuing the possibility of bias must be low. In some instances, judges have been frustrated in identifying expert witnesses who are free of conflict of interest because entire fields of science seem to be co-opted by payments from industry"?

Or how about the first section of the first chapter of the Manual: "A. Atomization"? Citing our least favorite case, Milward v. Acuity, the Manual frowns on the effort of courts to examine the premises, and the evidence allegedly supporting those premises, of an expert when determining whether his causal inference is warranted. Noting, very slyly and without disclosing their demand for transparency and accountability, that certain well known and respected authorities have concluded that ultimately the determination of causation is a matter of scientific judgment "reflecting the weight of the evidence", the Manual chastises those who might cock an eyebrow when it turns out that none of the "evidence" proffered by an expert actually supports his opinion. What duties would be left to a gatekeeper obliged to accept the mere ipse dixit of a well credentialed academic? The Manual, unsurprisingly, doesn't say.

Worse yet, and indicative of who, and what cause, was behind the effort, the Manual goes on to cite the new-ish Milward three more times. Once for the proposition that the unproveability of a theory is proof of the theory; once to support the rubber stamping of an expert's personalized and unexamined - weighing in the scales of his scientific judgment - "methodology"; and, once to reject the idea that statistical significance testing - the "it might be so" hurdle for hypothesis generation from statistics - is any business of federal judges.

The first chapter tellingly concludes that "there are serious concerns about whether ... the guidelines have resulted in trial judges encroaching on the province of the jury to ... judge the overall credibility of  ... scientific theories." We thought the whole point of Daubert was to ensure a better approximation of the truth by at least limiting the theories to be considered by lay juries to those that have a decent chance of being true. Guess not.

David Oliver is managing partner of the Houston office of Vorys, Sater, Seymour and Pease. His practice focuses on civil litigation involving allegations of injuries due to exposure to chemicals or pharmaceuticals; he holds degrees in both chemistry and biology. David is registered for DRI’s Annual Meeting. He is speaking at the Toxic Tort Committee CLE session on October 28.  

Bookmark and Share

 

Proximate cause is an element of all tort cases.  In asbestos cases, a recent decision by the U.S. Sixth Circuit has favorable implications for the issues of causation and take-home exposure.  See Martin v Cincinnati Gas & Elec.Co., No. 07-6485, 2009 U.S. App. LEXIS 1702 (6th Cir. Jan. 27, 2009). In that case, the plaintiff’s father had worked with underground power lines that contained asbestos during a period from 1951 to 1963.  The plaintiff, who was born in 1952, claimed exposure to asbestos carried home on work clothes his father wore home, as well as from the plaintiff’s own exposure as a welder and mechanic from 1979 to 1984.  The district court, applying Kentucky law, granted summary judgment to GM for lack of substantial factor causation when the plaintiff was a mechanic, and to CG&E and GE, the father’s employer and supplier, for a lack of duty to the plaintiff for the take-home exposure. 

As to causation, the court noted that Kentucky law requires that asbestos exposure from a defendant’s product be a substantial factor in causing the injury. The plaintiff argued that, “because mesothelioma is a progressive disease, any exposure is a substantial cause.” The Sixth Circuit rejected this argument, which has worked in many jurisdictions. The court noted, “[y]et one measure of whether an action is a substantial factor is ‘the number of other factors which contribute in producing the harm and the extent of the effect which they have in producing it.’” Id. (quoting RESTATEMENT (SECOND) OF TORTS  § 433(a)).  Also noting its earlier decision, Lindstrom v. A-C Product Liability Trust, 424 F.3d 488, 493 (6th Cir. 2005), the court observed that to hold “any exposure is a substantial cause” would render the substantial factor test “meaningless.”  Summary judgment thus was upheld on the issue of causation. 

As to take-home liability, whether CG&E and GE owed the plaintiff a duty of care under Kentucky law turned on foreseeability in light of what the defendants knew or should have known at the relevant times.  Specifically, the plaintiff had to show that each defendant “knew or should have known the danger of bystander asbestos exposure” when it provided asbestos-containing products to the defendant’s father.  In cases like this, plaintiffs’ experts rely upon published scientific papers to show that the hazards of asbestos were knowable years before the exposure in a given case, thereby making the danger foreseeable. 

The Sixth Circuit, however, framed the issue under Kentucky law more precisely, finding that Kentucky law imposes upon the defendant a duty to have “knowledge of pertinent matters . . . as a reasonable man would have.”  Id. (citing Pathways, Inc. v. Hammons, 113 S.W.3d 85, 90 (Ky. 2003) (quoting RESTATEMENT (SECOND) OF TORTS § 289(a))). This knowledge includes the “capacities of things and forces in so far as they are matters of common knowledge at the time and in the community.” Id. (quoting RESTATEMENT (SECOND) OF TORTS § 289(a)). 1

The plaintiff had no evidence that CG&E or GE had actual knowledge of the danger of take-home exposure during the relevant time periods – 1937 to 1955 when GE supplied asbestos products, 1951 to 1963 when CG&E employed plaintiff’s father. The plaintiff instead tried to prove constructive knowledge through published reports and studies. A 1911 study and subsequent ones in the 1930s only were concerned with neighbors of asbestos factories.  Plaintiff’s expert also opined that there was knowledge of the hazard in the 1950s, but he conceded “that the first studies of bystander exposure were not published until 1965.”  The court concluded that “[w]ithout any published studies or any evidence of industry knowledge of bystander exposure, there is nothing that would justify charging CG&E or GE with such knowledge during the time that Mr. Martin’s father was working with asbestos.”

Beyond the general fact that the Sixth Circuit upheld summary judgment on the issues of causation and take-home exposure, the decision is important to all jurisdictions. It suggests defendants would be well advised to use well-established tort concepts in conjunction with a careful reading of the Restatement in order to bring common sense back into the courtroom.  That approach here lead to an outright rejection of de minimis asbestos exposure as adequate evidence of causation. It also resulted in premises and supplier defendants being relieved of liability to bystanders when there was a complete lack of evidence that a reasonable person would have recognized that harm to bystanders was foreseeable at the time when the exposure occurred.

The outcome reached in Martin was aided by the amicus brief of Mark Behrens, partner at Shook, Hardy & Bacon, on behalf of the Coalition for Litigation Justice and other interested parties. The brief focused on the take-home exposure side of the case, but Mr. Behrens also has contributed to the body of arguments against de minimis exposure, namely an article he recently coauthored with William Anderson – The "Any Exposure" Theory An Unsound Basis for Asbestos Causation and Expert Testimony, 37 S.U. L. REV. 479 (2008).  It finally should be noted that the Martin decision is unpublished but citation is permitted as long as the decision is attached to the brief.  See FRAP 32.1; 6 Cir. R. 28(f). 

Bookmark and Share

Categories: Toxic Tort | Asbestos | Causation

Actions: E-mail | Comments

 
 

Submit Blog

If you wish to submit a blog posting for DRI Today, send an email to today@dri.org with "Blog Post" in the subject line. Please include article title and any tags you would like to use for the post.
 
DRI President's Blog
 
 

Search Blog


Recent Posts

Categories

Authors

Blogroll



Staff Login